Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.89USD
17 Aug 2018
Change (% chg)

-- (--)
Prev Close
$0.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
49,150
52-wk High
$1.34
52-wk Low
$0.78

Chart for

About

No overview information found for .

Overall

No Ratios Available.

Financials

  BLRX.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -- -- --
ROI: -- 2.89 12.63
ROE: -- 1.65 14.82

BRIEF-BioLineRx Reports Qtrly Loss Per Share $0.06

* QTRLY LOSS PER ORDINARY SHARE BASIC AND DILUTED $0.06 Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml Patients

* BIOLINERX TO PRESENT OVERALL SURVIVAL DATA AT EHA FROM PHASE 2A STUDY OF BL-8040 IN R/R AML PATIENTS

May 17 2018

BRIEF-Biolinerx Announces Grant Of European Patent Covering Use Of Bl-8040 With Cytarabine

* BIOLINERX ANNOUNCES GRANT OF EUROPEAN PATENT COVERING USE OF BL-8040 WITH CYTARABINE FOR TREATING ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 16 2018

BRIEF-BioLineRx Announces Notice of Allowance From USPTO for Patent Covering Immunotherapy for Treating Solid Tumors

* BIOLINERX ANNOUNCES NOTICE OF ALLOWANCE FROM USPTO FOR PATENT COVERING AGI-134 - A NOVEL IMMUNOTHERAPY FOR TREATING SOLID TUMORS

Mar 26 2018

BRIEF-Biolinerx Reports Year End 2017 Financial Results

* BIOLINE RX LTD - COMPANY HELD $49.5 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

Mar 06 2018

Earnings vs. Estimates